Quantcast

Latest Islets of Langerhans Stories

2008-10-24 15:00:09

BOTHELL, Wash., Oct. 24 /PRNewswire-FirstCall/ -- BioLife Solutions Inc. (BULLETIN BOARD: BLFS) , a leading developer and marketer of proprietary hypothermic storage and cryopreservation media products for cells, tissues, and organs, today announced that MicroIslet Inc. (BULLETIN BOARD: MIIS) , a biotechnology company engaged in developing and commercializing cellular therapies for patients with diabetes, has adopted HypoThermosol for preserving, transporting, and storing pancreatic source...

2008-10-21 09:00:12

Living Cell Technologies Limited (ASX: LCT; OTCQX: LVCLY) today announced that New Zealand Health Minister, the Honorable David Cunliffe, has approved an application from the company to conduct in New Zealand a Phase I/IIa clinical trial of DiabeCell(R), LCT's lead product candidate for the treatment of insulin dependent (Type 1) diabetes. "Obtaining approval to begin our clinical trial is a major milestone for the company and also makes it easier for LCT to obtain approvals in other...

2008-10-14 09:00:11

DiaKine Therapeutics, developers of drugs designed to cause diabetes to go into remission, announced today that a Phase 2 Clinical Trial with the Company's lead drug candidate, Lisofylline (LSF), is underway. Use of LSF may improve the long-term success of transplanting islets (the insulin-producing cells of the pancreas) into people with type 1 diabetes. The trial is part of the Clinical Islet Transplantation (CIT) Consortium created by National Institutes of Health. The protocol,...

2008-09-29 18:00:00

FRIENDLY bacteria in the gut may protect against insulin- dependent diabetes, a study suggests. In tests on mice, the bugs appeared to stop the rogue immune response that triggers the disease. Type 1 diabetes is caused by an autoimmune response which destroys insulin-producing islet cells in the pancreas. Scientists in America studied genetically engineered diabetic mice whose immune systems lacked a key protein that allowed them to respond to bacteria. When they were given back a...

2008-09-22 21:00:12

In tests on mice, the bugs appeared to stop the rogue immune response that triggers the disease.Type 1 diabetes is caused by an autoimmune response which destroys insulin-producing islet cells in the pancreas.About 300,000 people in the UK suffer from the disease. The condition often develops in childhood and has to be controlled with daily insulin jabs.The US study, of mice, showed that harmless bacteria could prevent type 1 diabetes. It also demonstrated the role played by an immune system...

2008-09-03 12:00:06

Research and Markets (http://www.researchandmarkets.com/research/d99eac/competitor_analysi) has announced the addition of the "Competitor Analysis: Emerging Diabetes Drugs" report to their offering. Emerging diabetes drugs consider beta cell mass and function as an important target The next generation of diabetes drugs still is focused on metabolic approaches, but activities to preserve or even regenerate pancreatic islet cell mass and function are gaining momentum This...

2008-08-26 18:00:15

Launching a counter-attack on the immune response that causes insulin-dependent diabetes may provide a revolutionary new way of treating the disease, research has shown. Scientists have found a way to isolate and kill defective immune system cells that wipe out insulin-producing cells in the pancreas. Type 1 diabetes is an autoimmune disease in which the body's "insulin factory" - pancreatic islet cells - is gradually destroyed by specialised white blood cells called "killer" T-cells....

2008-08-20 09:01:30

MicroIslet Inc. (OTCBB: MIIS, http://www.microislet.com), a biotechnology company engaged in the development and commercialization of cell therapies for diabetes, has appointed Brian D. Conn to the positions of Vice President Corporate Finance and Chief Financial Officer. Mr. Conn has served as a financial executive in high growth companies for over twenty years. He has extensive experience with M&A and capital transactions. Since 2000, Mr. Conn has held executive positions,...

2008-08-13 15:01:02

MicroIslet Inc. (OTCBB: MIIS, http://www.microislet.com), a biotechnology company engaged in the development and commercialization of cell therapies for diabetes, is pleased to report on the Company's presentation at the XXII International Congress Of The Transplantation Society Meeting, being held August 10-14, 2008, at the Sydney Convention & Exhibition Centre in Sydney, Australia. Drs. Ingrid Stuiver and Amaresh Basu, MicroIslet's Senior Director and Vice President of R&D,...

2008-07-17 00:00:35

Living Cell Technologies Limited (ASX: LCT) (PINKSHEETS: LVCLY) today announced that Professor Bob Elliott, Medical Director of LCT, will host a seminar on Friday, August 8, 2008, in Auckland, New Zealand for world leading medical scientists and specialists to discuss current developments with porcine islet transplant technologies. The one day meeting brings together experts with many years experience who are developing methods for delivering insulin producing cells to patients with insulin...


Word of the Day
grass-comber
  • A landsman who is making his first voyage at sea; a novice who enters naval service from rural life.
According to the OED, a grass-comber is also 'a sailor's term for one who has been a farm-labourer.'